Results 151 to 160 of about 20,052 (248)

Real‐world treatment trajectories preceding GLP‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate glucose‐lowering treatment trajectories preceding glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation in UK primary care, while assessing alignment with contemporary UK clinical guidelines, considering calendar time, cardiovascular disease (CVD) history, and obesity status.
Franziska S. Ulrich, Morten Frost Nielsen, Nicola Napoli, Andrea M. Burden   +3 more
wiley   +1 more source

Retrospective Study of Real-World Treatment Patterns of Subcutaneous Semaglutide Use Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in the United States

ClinicoEconomics and Outcomes Research
Yestle Kim,1 Ni Zeng,2 Jessamine P Winer-Jones,2 Machaon Bonafede,2 Francis Lobo,1 John O’Donnell,1 Taylor Ryan2 1Health Economics and Outcomes Research Madrigal Pharmaceuticals, Inc, West Conshohocken, PA, USA; 2Real World Evidence, Veradigm, Chicago ...
Kim Y, Zeng N, Winer-Jones JP, Bonafede M, Lobo F, O'Donnell J, Ryan T   +6 more
doaj  

Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications. [PDF]

Curr Cardiol Rep
Odeleye V, Singh N, Gautam S, Shannon E, Bibb WM, McClure M, Paul TK.   +6 more
europepmc   +1 more source

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa   +3 more
wiley   +1 more source

Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK. [PDF]

Endocr Connect
Van Sloten T, Hageman SHJ, Westerink J, Capucci S, Diogo da Rocha Fernandes J, Holloway S, Pijper A, Tikhonovsky N, Emerson S, Lincoff AM, Plutzky J, Lingvay I.   +11 more
europepmc   +1 more source

Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelines

Diabetes, Obesity and Metabolism, EarlyView.
Abstract The clinical management of metabolic dysfunction‐associated steatotic liver disease (MASLD) and metabolic dysfunction‐associated steatohepatitis (MASH) is undergoing rapid evolution, driven by advances in noninvasive diagnostics and the recent approval of liver‐directed therapies.
Fernando Bril
wiley   +1 more source

A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity. [PDF]

Healthcare (Basel)
Lee AH, Holmes-Walker DJ.
europepmc   +1 more source

Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Background Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) improve glycemic outcomes in people with type 2 diabetes, but their generalizability to routine clinical practice remains uncertain. Aim To evaluate the real‐world effectiveness of sustained GLP‐1 RA use on haemoglobin A1c (HbA1c) over 1 to 4.5 years, using dipeptidyl peptidase 4
Kathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, Hannah Karin Wood‐Kurland, Ulrik Pedersen‐Bjergaard, Mikkel Porsborg Andersen, Jens Michelsen, Henrik Imberg, Marcus Lind, Sara Hallström, Stefanie Lanzinger, Anders Munch, Johan Sebastian Ohlendorff, Thomas Alexander Gerds, Christian Torp‐Pedersen, The REDDIE Consortium   +15 more
wiley   +1 more source

Real‐world predictors of progression to type 2 diabetes among adults with prediabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Assess predictors of progression to type 2 diabetes (T2D) among patients with prediabetes. Materials and methods This case–control study assessed adults with prediabetes using US claims and EMR‐linked data from January 1, 2016, through January 31, 2024.
Tyler Dunn, Riddhi Doshi, Victoria Divino, Justin Chen, Michael Radin, Dajun Tian, Lin Xie, Carolina Solis‐Herrera   +7 more
wiley   +1 more source

Comparative effectiveness of semaglutide and dulaglutide combined with hypocaloric diet in newly diagnosed type 2 diabetes: a retrospective real-world study. [PDF]

BMC Endocr Disord
Cetiner S.
europepmc   +1 more source